Gilles Van Cutsem

Gilles Van Cutsem

Auto-generated profile, based on publicly available information

Gilles Van Cutsem

University of Luxembourg, Esch-Sur-Alzette, Luxembourg

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2010 in AIDS
Verified
Journal Article
Closed access
ABAndrew Boulle
Andrew Boulle
GCGilles Van Cutsem
Gilles Van Cutsem
KHKatherine Hilderbrand
Katherine Hilderbrand
CCCarol Cragg
Carol Cragg
MAMusaed Abrahams
Musaed Abrahams
GMGary Maartens
Gary Maartens
Objectives: We report on outcomes after 7 years of a community-based antiretroviral therapy (ART) programme in Khayelitsha, South Africa, with death registry linkages to correct for mortality under-ascertainment. Design: This is an observational cohort study. Methods: Since inception, patient-level clinical data have been prospectively captured on-site into an electronic patient information system. Patients with available civil identification numbers who were lost to follow-up were matched with the national death registry to ascertain their vital status. Corrected mortality estimates weighted these patients to represent all patients lost to follow-up. CD4 cell count outcomes were reported conditioned on continuous virological suppression. Results: Seven thousand, three hundred and twenty-three treatment-naive adults (68% women) started ART between 2001 and 2007, with annual enrolment increasing from 80 in 2001 to 2087 in 2006. Of 9.8% of patients lost to follow-up for at least 6 months, 32.8% had died. Corrected mortality was 20.9% at 5 years (95% confidence interval 17.9–24.3). Mortality fell over time as patients accessed care earlier (median CD4 cell count at enrolment increased from 43 cells/μl in 2001 to 131 cells/μl in 2006). Patients who remained virologically suppressed continued to gain CD4 cells at 5 years (median 22 cells/μl per 6 months). By 5 years, 14.0% of patients had failed virologically and 12.2% had been switched to second-line therapy. Conclusion: At a time of considerable debate about future global funding of ART programmes in resource-poor settings, this study has demonstrated substantial and durable clinical benefits for those able to access ART throughout this period, in spite of increasing loss to follow-up.

1 August 2014 in The Lancet
Verified
Journal Article
Closed access
MRMolebogeng X Rangaka
Molebogeng X Rangaka
RWRobert J Wilkinson
Robert J Wilkinson
ABAndrew Boulle
Andrew Boulle
JGJudith R Glynn
Judith R Glynn
KFKatherine Fielding
Katherine Fielding
GMGary Maartens
Gary Maartens

13 February 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMiguel Angel Luque-Fernandez
Miguel Angel Luque-Fernandez
GCGilles Van Cutsem
Gilles Van Cutsem
EGEric Goemaere
Eric Goemaere
KHKatherine Hilderbrand
Katherine Hilderbrand
MSMichael Schomaker
Michael Schomaker
ABAndrew Boulle
Andrew Boulle
Innovative models of care are required to cope with the ever-increasing number of patients on antiretroviral therapy in the most affected countries. This study, in Khayelitsha, South Africa, evaluates the effectiveness of a group-based model of care run predominantly by non-clinical staff in retaining patients in care and maintaining adherence. Participation in “adherence clubs” was offered to adults who had been on ART for at least 18 months, had a current CD4 count >200 cells/ml and were virologically suppressed. Embedded in an ongoing cohort study, we compared loss to care and virologic rebound in patients receiving the intervention with patients attending routine nurse-led care from November 2007 to February 2011. We used inverse probability weighting to estimate the intention-to-treat effect of adherence club participation, adjusted for measured baseline and time-varying confounders. The principal outcome was the combination of death or loss to follow-up. The secondary outcome was virologic rebound in patients who were virologically suppressed at study entry. Of 2829 patients on ART for >18 months with a CD4 count above 200 cells/µl, 502 accepted club participation. At the end of the study, 97% of club patients remained in care compared with 85% of other patients. In adjusted analyses club participation reduced loss-to-care by 57% (hazard ratio [HR] 0.43, 95% CI = 0.21–0.91) and virologic rebound in patients who were initially suppressed by 67% (HR 0.33, 95% CI = 0.16–0.67). Patient adherence groups were found to be an effective model for improving retention and documented virologic suppression for stable patients in long term ART care. Out-of-clinic group-based models facilitated by non-clinical staff are a promising approach to assist in the long-term management of people on ART in high burden low or middle-income settings.

28 May 2014 in Tropical Medicine & International Health
Verified
Journal Article
Closed access
PDF file
MBMarielle Bemelmans
Marielle Bemelmans
SBSaar Baert
Saar Baert
EGEric Goemaere
Eric Goemaere
LWLynne Wilkinson
Lynne Wilkinson
MVMartin Vandendyck
Martin Vandendyck
NFNathan Ford
Nathan Ford

10 September 2010 in AIDS
Verified
Journal Article
Closed access
MCMorna Cornell
Morna Cornell
AGAnna Grimsrud
Anna Grimsrud
LFLara Fairall
Lara Fairall
MFMatthew P Fox
Matthew P Fox
GCGilles van Cutsem
Gilles van Cutsem
LMLandon Myer
Landon Myer
Objective: Little is known about the temporal impact of the rapid scale-up of large antiretroviral therapy (ART) services on programme outcomes. We describe patient outcomes [mortality, loss-to-follow-up (LTFU) and retention] over time in a network of South African ART cohorts. Design: Cohort analysis utilizing routinely collected patient data. Methods: Analysis included adults initiating ART in eight public sector programmes across South Africa, 2002–2007. Follow-up was censored at the end of 2008. Kaplan–Meier methods were used to estimate time to outcomes, and proportional hazards models to examine independent predictors of outcomes. Results: Enrolment (n = 44 177, mean age 35 years; 68% women) increased 12-fold over 5 years, with 63% of patients enrolled in the past 2 years. Twelve-month mortality decreased from 9% to 6% over 5 years. Twelve-month LTFU increased annually from 1% (2002/2003) to 13% (2006). Cumulative LTFU increased with follow-up from 14% at 12 months to 29% at 36 months. With each additional year on ART, failure to retain participants was increasingly attributable to LTFU compared with recorded mortality. At 12 and 36 months, respectively, 80 and 64% of patients were retained. Conclusion: Numbers on ART have increased rapidly in South Africa, but the programme has experienced deteriorating patient retention over time, particularly due to apparent LTFU. This may represent true loss to care, but may also reflect administrative error and lack of capacity to monitor movements in and out of care. New strategies are needed for South Africa and other low-income and middle-income countries to improve monitoring of outcomes and maximize retention in care with increasing programme size.

1 March 2007 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MRMolebogeng Xheeda Rangaka
Molebogeng Xheeda Rangaka
Katalin A WilkinsonKatalin A Wilkinson
Katalin A Wilkinson
RSRonnett Seldon
Ronnett Seldon
GCGilles Van Cutsem
Gilles Van Cutsem
GMGraeme Ayton Meintjes
Graeme Ayton Meintjes
RWRobert J. Wilkinson
Robert J. Wilkinson
Rationale: Two forms of the IFN-γ release assay (IFNGRA) to detect tuberculosis infection are available, but neither has been evaluated in comparable HIV-infected and uninfected persons in a high tuberculosis incidence environment. Objective: To compare the ability of the T-SPOT.TB (Oxford Immunotec, Abingdon, UK), QuantiFERON-TB Gold (Cellestis, Melbourne, Australia), and Mantoux tests to identify latent tuberculosis in HIV-infected and uninfected persons. Methods: A cross-sectional study of 160 healthy adults without active tuberculosis attending a voluntary counseling and testing center for HIV infection in Khayelitsha, a deprived urban South African community with an HIV antenatal seroprevalence of 33% and a tuberculosis incidence of 1,612 per 100,000. Measurements and Main Results: One hundred and sixty (74 HIV+ and 86 HIV−) persons were enrolled. A lower proportion of Mantoux results was positive in HIV-infected subjects compared with HIV-uninfected subjects (p < 0.01). By contrast, the proportion of positive IFNGRAs was not significantly different in HIV-infected persons for the T-SPOT.TB test (52 vs. 59%; p = 0.41) or the QuantiFERON-TB Gold test (43 and 46%; p = 0.89). Fair agreement between the Mantoux test (5- and 10-mm cutoffs) and the IFNGRA was seen in HIV-infected people (κ = 0.52–0.6). By contrast, poor agreement between the Mantoux and QuantiFERON-TB Gold tests was observed in the HIV-uninfected group (κ = 0.07–0.30, depending on the Mantoux cutoff). The pattern was similar for T-SPOT.TB (κ = 0.18–0.24). Interpretation: IFNGRA sensitivity appears relatively unimpaired by moderately advanced HIV infection. However, agreement between the tests and with the Mantoux test varied from poor to fair. This highlights the need for prospective studies to determine which test may predict the subsequent risk of tuberculosis.